Shots:

• Depomed changes name to Assertio Therapeutics on Aug 15- 2018- with a strategic focus on our neurology- orphan and specialty medicines
• The rebranding is done after Senate committee opened probe for opioid marketing last year
• Assertio’s common stock has started trading with new ticker “ASRT” from Aug 15- 2018. Depomed also completed the relocation of headquarters from Newark to Lake Forest

Ref: Assertio Therapeutics| Image:  Smarteranalyst